Cipla jumps as its step-down associate company gets regulatory update for intravenous tramadol

18 Dec 2020 Evaluate

Cipla is currently trading at Rs. 792.95, up by 9.75 points or 1.24% from its previous closing of Rs. 783.20 on the BSE.

The scrip opened at Rs. 785.00 and has touched a high and low of Rs. 794.35 and Rs. 781.50 respectively. So far 172127 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 829.00 on 13-Oct-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 798.00 and Rs. 772.00 respectively. The current market cap of the company is Rs. 63931.01 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 39.82% and 23.48% respectively.

Cipla’s step-down associate company Avenue Therapeutics has received an update from the US health regulator for its new drug application for intravenous (IV) tramadol. Avenue Therapeutics' IV tramadol is intended to treat patients in acute pain who require an opioid.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×